References
- 1. Kanis JA, McCloskey EV, Johansson H, et al. A reference standard for the description of osteoporosis. Bone. 2008;42(3):467-75.10.1016/j.bone.2007.11.00118180210
- 2. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Available at http://www.nof.org/professionals/ clinical-guidelines. 2011
- 3. Bono CM, Einhorn TA. Overview of osteoporosis: pathophysiology and determinants of bone strength. Eur Spine J. 2003;12(2):90-6.
- 4. Ringe JD, Farahmand P. Advances in the management of corticosteroidinduced osteoporosis with bisphosphonates. Clin Rheumatol. 2007;26(4):474-84.10.1007/s10067-006-0467-z17122953
- 5. Raisz LG. Pathogenesis of osteoporosis: concepts, confl icts, and prospects. J Clin Invest. 2005;115(12):3318-25.10.1172/JCI27071129726416322775
- 6. http://www.shef.ac.uk/FRAX
- 7. Schwartz AV, Vittinghoff E, Bauer DC, et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA. 2011;305(21):2184-92.10.1001/jama.2011.715328738921632482
- 8. Lecart MP, Reginster JY. Current options for the management of postmenopausal osteoporosis. Expert Opin Pharmacother. 2011;12(16): 2533-52.10.1517/14656566.2011.61812321916810
- 9. Sandhu SK, Hampson G. The pathogenesis, diagnosis, investigation and management of osteoporosis. J Clin Pathol. 2011;64(12):1042-50.10.1136/jcp.2010.07784221896577
- 10. World Health Organization. WHO scientifi c group on the assessment of osteoporosis at primary health care level: summary meeting report. Available at http://www.who.int/chp/topics/Osteoporosis.pdf. 2012.
- 11. Silverman SL. Selecting patients for osteoporosis therapy. Ann N Y Acad Sci. 2007;1117:264-72.10.1196/annals.1402.04218056046
- 12. Warensjö E, Byberg L, Melhus H, et al. Dietary calcium intake and risk of fracture and osteoporosis: prospective longitudinal cohort study. BMJ. 2011;342: d1473.10.1136/bmj.d1473310133121610048
- 13. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med. 2009;169(6):551-61.10.1001/archinternmed.2008.60019307517
- 14. Watts NB, Bilezikian JP, Camacho PM, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2010;16(3):1-37.10.4158/EP.16.S3.1
- 15. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125-37.10.1056/NEJMoa06246216837676
- 16. Geusens P. Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment. Curr Osteoporos Rep 2009, 7 (1):12-7.10.1007/s11914-009-0003-619239824
- 17. National Osteoporosis Foundation. Fast facts. Available at http://www.nof.org/node/40. 2012.
- 18. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354(8):821-31.10.1056/NEJMoa04445916495394
- 19. Blake GM, Fogelman I. Long-term effect of strontium ranelate treatment on BMD. J Bone Miner Res. 2005;20(11):1901-4. 10.1359/JBMR.05081016234961